Evaluating the Effects of Sugar Shift® Symbiotic on Microbiome Composition and LPS Regulation: A Double-Blind, Placebo-Controlled Study DOI Creative Commons
Gissel Garcı́a,

Josanne Soto,

Michael Netherland

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(12), P. 2525 - 2525

Published: Dec. 7, 2024

(1) Background: This study evaluated the effects of BiotiQuest® Sugar Shift®, a novel probiotic formulation, for its impact on gut microbiome composition and metabolic health in type 2 diabetes mellitus (T2D). T2D is characterized by chronic inflammation imbalances, yet therapeutic potential targeted probiotics remains underexplored. (2) Methods: In 12-week randomized, double-blind, placebo-controlled trial, 64 adults with received either Shift or placebo capsules twice daily. Each dose provided 18 billion CFU eight GRAS-certified bacterial strains prebiotics. Clinical samples were analyzed markers, changes assessed using 16S rRNA sequencing metagenomics. (3) Results: significantly reduced serum lipopolysaccharide (LPS) levels, improved insulin sensitivity (lower HOMA-IR scores), increased short-chain fatty acid (SCFA)-producing genera, including Bifidobacterium, Faecalibacterium, Fusicatenibacter, Roseburia. Pro-inflammatory taxa like Enterobacteriaceae decreased, LPS biosynthesis genes SCFA production genes. The Lachnospiraceae:Enterobactericeae ratio emerged as biomarker inflammation. (4) Conclusions: These findings demonstrate to restore homeostasis, reduce inflammation, improve T2D. Further studies are warranted explore long-term efficacy broader application disease management.

Language: Английский

Evaluating the Effects of Sugar Shift® Symbiotic on Microbiome Composition and LPS Regulation: A Double-Blind, Placebo-Controlled Study DOI Creative Commons
Gissel Garcı́a,

Josanne Soto,

Michael Netherland

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(12), P. 2525 - 2525

Published: Dec. 7, 2024

(1) Background: This study evaluated the effects of BiotiQuest® Sugar Shift®, a novel probiotic formulation, for its impact on gut microbiome composition and metabolic health in type 2 diabetes mellitus (T2D). T2D is characterized by chronic inflammation imbalances, yet therapeutic potential targeted probiotics remains underexplored. (2) Methods: In 12-week randomized, double-blind, placebo-controlled trial, 64 adults with received either Shift or placebo capsules twice daily. Each dose provided 18 billion CFU eight GRAS-certified bacterial strains prebiotics. Clinical samples were analyzed markers, changes assessed using 16S rRNA sequencing metagenomics. (3) Results: significantly reduced serum lipopolysaccharide (LPS) levels, improved insulin sensitivity (lower HOMA-IR scores), increased short-chain fatty acid (SCFA)-producing genera, including Bifidobacterium, Faecalibacterium, Fusicatenibacter, Roseburia. Pro-inflammatory taxa like Enterobacteriaceae decreased, LPS biosynthesis genes SCFA production genes. The Lachnospiraceae:Enterobactericeae ratio emerged as biomarker inflammation. (4) Conclusions: These findings demonstrate to restore homeostasis, reduce inflammation, improve T2D. Further studies are warranted explore long-term efficacy broader application disease management.

Language: Английский

Citations

1